Recent events
Recent events tied to this brand in public sources.
Back to profile11 entries
2022
La Jolla Pharmaceutical sues over Giapreza patents
La Jolla Pharmaceutical Company, La Jolla Pharma, LLC, and George Washington University filed a case against Gland Pharma Limited, Shanghai Fosun Pharmaceutical Group Co LTD, and Fosun Pharma USA Inc., alleging patent violations related to Giapreza.
2022
Fosun Pharma and Insilico Medicine announce AI drug-discovery partnership
Fosun Pharma and Insilico Medicine announced a global strategic partnership to advance AI-driven drug research across multiple targets, including development work on Insilico Medicine’s QPCTL project. The agreement includes a $13 million upfront payment to Insilico Medicine, milestone payments, profit sharing for the QPCTL project, and an equity investment by Fosun Pharma.
2021
Fosun Industrial signs Taiwan vaccine sales agreement
Fosun Industrial signed an agreement to sell a total of 10 million doses of the mRNA COVID-19 vaccine to TSMC, Hon Hai and the Yongling Foundation for supply to Taiwan.
2021
BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defect
BioNTech notified Fosun Pharma of a vial-cap defect in BNT162b2 batch 210102 supplied to Hong Kong and Macau. BioNTech and Fosun Pharma began investigating the cause, and the batch was paused for vaccination until the investigation ends; Fosun Pharma also said batch 210104 intended for Hong Kong would be stored and not sent to vaccination sites pending further notice.
2020
Fosun Pharma appoints Wu Yifang chairman and CEO
Fosun Pharma announced that Wu Yifang would serve as its executive director, chairman and CEO, succeeding Chen Qiyu as chairman.
2020
Fosun Pharma and Sinopharm sign vaccine logistics partnership
Fosun Pharma and Sinopharm Holding signed a strategic logistics cooperation agreement for the BioNTech mRNA vaccine, including plans to jointly establish a vaccine cold-chain system and improve storage, transport and distribution services.
2020
Fosun Pharma and Polyphor sign Balixafortide license agreement
Fosun Pharma and Polyphor announced an exclusive license agreement for Balixafortide in mainland China, Hong Kong, and Macau and Taiwan. Fosun Pharma’s subsidiary is authorized to clinically develop and commercialize the drug in the territory.
2020
Hong Kong Stock Exchange approves Gland Pharma overseas listing proposal
Fosun Pharma announced that the Hong Kong Stock Exchange had approved the proposed overseas listing of Gland Pharma. The article says the listing still required, among other things, approval from relevant Indian regulators and was not guaranteed to proceed.
2020
Pfizer responds to controversy over China’s exclusion from vaccine collaboration
Pfizer said its collaboration with BioNTech did not include China because BioNTech had already partnered with Fosun Pharma for the Chinese market. Pfizer said it was working to resolve details and was committed to access to medicines and vaccines for patients in China and globally.
2019
ACCA and Fosun Pharma sign strategic cooperation memorandum
ACCA and Fosun Pharma signed a strategic cooperation memorandum covering finance-management transformation, finance talent development, and support for Fosun Pharma's global development.
2019
Fosun Pharma wins two 2019 Chinese pharmaceutical company awards
Fosun Pharma received the “2019 China Pharmaceutical Listed Companies Top 10 Most Valuable for Investment” and “2019 China Pharmaceutical Enterprise Social Responsibility Leader” awards at the 2019 China Pharmaceutical Entrepreneurs, Scientists and Investors Conference.